Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis

Clinical and Experimental Rheumatology

Volumn 25, Issue 6 SUPPL. 47, 2007, Pages

  Alexanderson, Helene ^a   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dermatomyositis; Diagnostic tools; Disease activity score; Functional index (FI); Myositis acitivities profile (MAP); Outcome measures; Polymyositis

Indexed keywords

AZATHIOPRINE; CREATINE KINASE MM; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHOTREXATE; MUSCLE ENZYME;

ARTHROPATHY; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG MEGADOSE; ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE QUALITY; HEART DISEASE; HUMAN; KINESIOTHERAPY; LABORATORY TEST; LUNG DISEASE; MUSCLE EXERCISE; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOMES RESEARCH; POLYMYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SKIN DISEASE;

DERMATOMYOSITIS; DISEASE; HUMANS; POLYMYOSITIS; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 36448931658     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. CORDEIRO AC, ISENBERG DA: Treatment of inflammatory myopathies. Postgrad Med J 2006; 82: 417-24.
2. WIESINGER GF, QUITTAN M, ARINGER M et al.: Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37: 196-200.
3. WIESINGER GF, QUITTAN M, GRANINGER M et al.: Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37: 1338-42.
4. ALEXANDERSON H, STENSTROM CH, LUNDBERG I: Safety of a home exercise programme in patients with polymyositis and dermatomyositis: A pilot study. Rheumatology (Oxford) 1999; 38: 608-11.
5. ALEXANDERSON H, STENSTROM CH, JENNER G, LUNDBERG I: The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29: 295-301.
6. VARJU C, PETHO E, KUTAS R, CZIRIAK L: The effect of physical exercise following acute disease exacerbation in patients with dermato/ polymyositis. Clin Rehabil 2003; 17: 83-7.
7. ALEXANDERSON H, DASTMALCHI M, ESBJORNSSON-LILJEDAHL M, OPAVA CH, LUNDBERG IE: Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007; 57: 768-77.
8. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
9. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
10. VAN DER PAS J, HENGSTMAN GJ, TER LAAK HJ. BORM GF. VAN ENGELEN BG: Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75: 136-9.
11. LAMPA J, NENNESMO I, EINARSDOTTIR H, LUNDBERG I: MRI guided muscle biopsy confirmed polymyositis diagnosis in a patient with interstitial lung disease. Ann Rheum Dis 2001; 60: 423-6.
12. TOMASOVA STUDYNKOVA J, CHARVAT F, JAROSOVA K, VENCOVSKY J: The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2007; 46: 1174-9 (E-pub 2007 May 10).
13. BROUWER R, HENGSTMAN GJ, VREE EGBERTS W et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116-23.
14. HENGSTMAN GJ, BROUWER R, EGBERTS WT et al.: Clinical and serological characteristics of 125 Dutch myositis patients. Myositis-specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002; 249: 69-75.
15. LOVE LA, LEFF RL, FRASER DD et al.: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360-74.
16. TARGOFF IN, MAMYROVA G, TRIEU EP et al. and the Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.
17. RIDER LG, FELDMAN BM, PEREZ MD et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997; 40: 1976-83.
18. FATHI M, DASTMALCHI M, RASMUSSEN E, LUNDBERG IE, TORNLING G: Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297-301.
19. MILLER FW, RIDER LG, CHUNG YL et al. for the International Myositis Outcome Assessment Collaborative Study Group: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1262-73.
20. IMACS website. Available at: https://dirapps.niehs.nih.gov/imacs/
21. RIDER LG, GIANNINI EH, BRUNNER HI et al. and the International Myositis Assessment and Clinical Studies Group: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90.
22. ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult-onset disease. Rheumatology 2004; 43: 49-54.
23. WORLD HEALTH ORGANIZATION: The International Classification of Functioning, Disability and Health. Geneva, World Health Organization, 2001.
24. RIDER LG: Outcome assessment in the adult and juvenile idiopathic myopathies. Rheum Dis Clin North Am 2002; 28: 935-77.
25. CHERIN P, PELLETIER S, TEIXEIRA A et al.: Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467-74.
26. DANIELI MG, MALCANGI G, PALMIERI C et al.: Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 37-41.
27. HENGSTMAN GJD, VAN DEN HOOGEN FHJ, BARRERA P et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003; 50: 10-5.
28. BADRISING UA, MAAT-SCHIEMAN ML, FERRARI MD et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51: 369-72.
29. ARNARDOTTIR S, ALEXANDERSON H, LUNDBERG IE, BORG K: Sporadic inclusion body myositis: Pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35: 31-5.
30. JOSEFSON A, ROMANUS E, CARLSSON J: A functional index in myositis. J Rheumatol 1996; 23: 1380-4.
31. VENCOVSKY J, JAROSOVA K, MACHACEK S et al.: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29: 95-102.
32. HEIKKILÄ S, VIITANEN JV, KAUTIAINEN H, RAJAMAKI T, MANTYVUO P, HARJU T: Rehabilitation in myositis. Physiotherapy 2001; 87: 301-9.
33. ALEXANDERSON H, BROMAN L, TOLLBACK A, JOSEFSON A, LUNDBERG IE, STENSTROM CH: Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006; 55: 114-22.
34. ALEXANDERSON H, DASTMALCHI M, LUNDBERG IE: Patients with chronic inflammatory myopathies have reduced muscle endurance rather than reduced muscle strength. Arthritis Rheum 2006; 54 (Suppl.): 1639: S658.
35. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
36. HUBER AM, HICKS JE, LACHENBRUCH PA et al.: For the Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001; 28: 1106-11.
37. ALEXANDERSON H, LUNDBERG IE, STENSTROM CH: Development of the myositis activities profile - validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 2002; 29: 2386-92.
38. WORLD HEALTH ORGANIZATION: International Classification of Impairment, Disability and Handicap, Beta-2 Draft, full version. Geneva, World Health Organization, 1999.
39. KIRWAN JR, HEWLETT SE, HEIBERG T et al.: Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2005; 32: 2250-6.
40. BACKMAN CL: Outcome measures for arthritis care research: Recommendations from the CARE III conference. J Rheumatol 2006; 33: 1908-11.
41. TUGWELL P, BOMBARDIER C, BUCHANAN WW, GOLDSMITH CH, GRACE E, HANNA B: The MACTAR Patient Preference Disability Questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987; 14: 446-51.
42. VERHOEVEN AC, BOERS M, VAN DER LIDEN S: Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. J Rheumatol 2000; 27: 2801-9.
43. ALEMO-MUNTERS L, VAN VOLLENHOVEN R, ALEXANDERSON H: Measurement properties of the Swedish MACTAR. Arthritis Rheum 2006; 54 (Suppl.): S503.
44. WARE JE, SHERBOURNE CD: The MOS 36-item short-form health survey: Conceptual framework and item selection. Med Care 1992; 30: 473-83.
45. SULTAN SM, IOANNOU Y, MOSS K, ISENBERG DA: Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology (Oxford) 2002; 41: 22-6.
46. PARK JH, VITAL TL, RYDER NM et al.: Magnetic resonance imaging and p-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994; 37: 736-46.
47. PFLEIDERER B, LANGE J, LOSKE KD, SUNDERKOTTER C: Metabolic disturbances during short exercises in dermatomyositis revealed by real-time functional 31P magnetic resonance spectroscopy. Rheumatology (Oxford) 2004; 43: 696-703.
48. WEBER MA, WEBER MA, JAPPE U et al.: Contrast-enhanced ultrasound in dermatomyositis and polymyositis. J Neurol 2006; 253: 1625-32.